Agios Pharm Stock Beta
| AGIO Stock | USD 57.51 1.83 3.29% |
Agios Pharm fundamentals help investors to digest information that contributes to Agios Pharm's financial success or failures. It also enables traders to predict the movement of Agios Stock. The fundamental analysis module provides a way to measure Agios Pharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Agios Pharm stock.
Agios | Beta |
Agios Pharm Company Beta Analysis
Agios Pharm's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Agios Pharm Beta | 0.75 |
Most of Agios Pharm's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Agios Pharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Agios Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Agios Pharm is extremely important. It helps to project a fair market value of Agios Stock properly, considering its historical fundamentals such as Beta. Since Agios Pharm's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Agios Pharm's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Agios Pharm's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Agios Pharm has a Beta of 0.751. This is 12.67% lower than that of the Biotechnology sector and 45.97% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Agios Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Agios Pharm's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Agios Pharm could also be used in its relative valuation, which is a method of valuing Agios Pharm by comparing valuation metrics of similar companies.Agios Pharm is currently under evaluation in beta category among its peers.
Agios Pharm ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Agios Pharm's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Agios Pharm's managers, analysts, and investors.Environmental | Governance | Social |
Agios Pharm Institutional Holders
Institutional Holdings refers to the ownership stake in Agios Pharm that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Agios Pharm's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Agios Pharm's value.| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.2 M | Bvf Inc | 2024-09-30 | 1.2 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.1 M | Rock Springs Capital Management Lp | 2024-06-30 | 1 M | Bnp Paribas Investment Partners Sa | 2024-06-30 | 911.2 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 882.7 K | Fisher Asset Management, Llc | 2024-09-30 | 855.3 K | Deutsche Bank Ag | 2024-06-30 | 662.2 K | Gw&k Investment Management, Llc | 2024-09-30 | 630.9 K | Farallon Capital Management, L.l.c. | 2024-09-30 | 5.7 M | Vanguard Group Inc | 2024-09-30 | 5.5 M |
As returns on the market increase, Agios Pharm's returns are expected to increase less than the market. However, during the bear market, the loss of holding Agios Pharm is expected to be smaller as well.
Agios Fundamentals
| Return On Equity | 0.54 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | 20.51 % | ||||
| Operating Margin | (11.47) % | ||||
| Current Valuation | 2.23 B | ||||
| Shares Outstanding | 57.03 M | ||||
| Shares Owned By Insiders | 1.50 % | ||||
| Shares Owned By Institutions | 98.50 % | ||||
| Number Of Shares Shorted | 4.34 M | ||||
| Price To Earning | 1.26 X | ||||
| Price To Book | 1.95 X | ||||
| Price To Sales | 96.60 X | ||||
| Revenue | 26.82 M | ||||
| Gross Profit | 12.54 M | ||||
| EBITDA | (384.86 M) | ||||
| Net Income | (352.09 M) | ||||
| Cash And Equivalents | 819.31 M | ||||
| Cash Per Share | 14.95 X | ||||
| Total Debt | 72 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 17.98 X | ||||
| Book Value Per Share | 28.53 X | ||||
| Cash Flow From Operations | (296.06 M) | ||||
| Short Ratio | 9.39 X | ||||
| Earnings Per Share | 11.66 X | ||||
| Target Price | 53.88 | ||||
| Number Of Employees | 383 | ||||
| Beta | 0.75 | ||||
| Market Capitalization | 3.18 B | ||||
| Total Asset | 937.12 M | ||||
| Retained Earnings | (822.65 M) | ||||
| Working Capital | 765.88 M | ||||
| Current Asset | 337.33 M | ||||
| Current Liabilities | 52.89 M | ||||
| Net Asset | 937.12 M |
About Agios Pharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Agios Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Agios Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Agios Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Agios Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.Moving against Agios Stock
| 0.89 | TCHH | Trustcash Holdings | PairCorr |
| 0.77 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.72 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.64 | ME | 23Andme Holding | PairCorr |
| 0.64 | AGL | agilon health Buyout Trend | PairCorr |
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Agios Pharm Piotroski F Score and Agios Pharm Altman Z Score analysis. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 11.66 | Revenue Per Share 0.582 | Quarterly Revenue Growth 0.212 | Return On Assets (0.18) | Return On Equity 0.5366 |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.